Previous 10 | Next 10 |
2023-07-13 09:05:00 ET Healthcare stocks, particularly pharmaceutical stocks with solid dividends, make great long-term investments. In general, the need for healthcare products and services is stable, even during economic downturns. When high interest rates in early 2022 caused sev...
2023-07-07 03:12:00 ET Summary Rose's Income Garden portfolio saw 39 companies pay dividends in June, with seven raises and one cut; the portfolio yield is approximately 5.2% and its value increased by 1.75% YTD excluding dividends. The portfolio, which consists of 80 stocks from ...
2023-07-05 06:08:00 ET For a generic drugmaker like Viatris (NASDAQ: VTRS) , big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining strong cash flows that enable returning capital to investors. ...
2023-07-03 15:50:36 ET Summary FDA approval of Revance Therapeutics, Inc.'s DAXXIFY for glabellar lines in the U.S. achieved; Initial launch brought in revenues of $15.4 million. A supplemental Biologics Licensing Application of DAXXIFY for adults with cervical dystonia has been a...
2023-06-29 05:02:34 ET For further details see: Goldman adds 39 new stocks to its Sharpe Ratio basket with megacaps absent
NEW YORK, NY / ACCESSWIRE / June 28, 2023 / Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS) of a class action securities lawsuit. The lawsuit on behalf of Viatris investors has been commenced in the United States District Court for the W...
Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023 PR Newswire PITTSBURGH , June 28, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open...
2023-06-23 09:50:46 ET Barclays downgraded Viatris Inc. ( NASDAQ: VTRS ) to Underweight from Equal Weight on Friday, noting that despite its low valuation, the generic drugmaker will likely remain a "show-me narrative" until there is clarity on its future strategy. The analyst B...
2023-06-20 05:53:32 ET Summary Viatris, a healthcare company, faces weakening fundamentals and significant risks, including uncertainty regarding its execution plan. Despite these challenges, the company has growth opportunities, with over $3 billion in annual sales expected to ma...
2023-06-15 12:37:07 ET Summary Viatris remains a dirt cheap stock in a frothy market and pays a well-covered dividend yield. It continues to make progress towards deleveraging, and could return substantial capital to shareholders in 2024. With market sentiment working against ...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...